Loading quotes...
Forecast
The analysts' average price target is €10.82 (-4.25%). The median is €10.70 (-5.31%).
| Buy |
18 |
| Hold |
8 |
| Sell |
0 |
News Go to news feed
Phreesia reports mixed Q2 results – revenue above, EPS well below expectations
Phreesia reported Q2 revenue of $129.5m (+10% YoY) and adjusted EPS of $0.03 versus consensus $0.09. Adjusted EBITDA rose to $32.9m with a 25% margin, and the company generated positive operating and free cash flow. The stock fell 7.59% in after-hours trading; Phreesia confirmed its full-year outlook of $510–520m in revenue and $125–135m in adjusted EBITDA. Management cited AccessOne, ProviderConnect and AI initiatives as growth drivers but sees near-term earnings and seasonality risks. » More on de.investing.com
Phreesia exceeds Q1 earnings expectations significantly and reports third consecutive profitable quarter
Phreesia reported Q1 of fiscal 2027 earnings per share of $0.05 versus $0.01 expected and revenue of $130.9 million (+13% year over year). Adjusted EBITDA rose 46.6% to $30.5 million and the margin improved to 23%. The company achieved a net profit of $3.0 million after a loss in the prior year and saw particularly strong revenue growth of 40% in its payment solutions segment. The stock rose about 2% in after-hours trading, and Phreesia confirmed guidance with positive EPS and revenue growth for upcoming periods. » More on de.investing.com
Wells Fargo keeps Overweight on Phreesia but cuts price target to $15
Wells Fargo maintained an Overweight rating on Phreesia and lowered its price target to $15, citing sharply decelerated fiscal 2027 revenue guidance driven by the Network segment despite constructive recent channel checks. Citizens recently downgraded Phreesia to Market Perform, noting disappointing revenue outlook and slowing growth in the largest subscription and related services segment. Phreesia posted Q4 adjusted EBITDA of $29.4M and revenue of $127.1M, reported positive GAAP net income of $2.3M and exceeded $100M in adjusted EBITDA and $50M in free cash flow for fiscal 2026. » More on finance.yahoo.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | July 2026 | YoY |
|---|---|---|
| Revenue | 112.21m | 9.32% |
| Gross profit | 66.02m | 5.27% |
| Net profit | 1.66m | 190.39% |
| EBITDA | 18.24m | 187.94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €728.57m |
Number of shares | 62.07m |
52-week high/low | €20.78 - €6.93 |
| Dividends | No |
Beta | 0.84 |
P/E ratio | 76.48 |
PEG ratio | -0.24 |
P/B ratio | 2.19 |
P/S ratio | 1.61 |
Company profile
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
| Name | Phreesia |
| CEO | Chaim Indig |
| Headquarters | Wilmington,
de USA |
| Website | |
| Sector | Industrials |
| Industry | Commercial Services & Supplies |
| IPO | 18/07/2019 |
| Employees | 1,789 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | PHR |
London Stock Exchange | 0A23.L |
Frankfurt | 19P.F |
Düsseldorf | 19P.DU |
London | 0A23.L |
München | 19P.MU |